Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia
The Journal of Clinical Pharmacology · 2024
DOI: 10.1002/jcph.2430 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Pharmacology, 2024. Verfasst von Wei Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Me…. Hauptthemen laut MEDLINE: Anemia, Aplastic, Benzoates, Hydrazines, Pyrazoles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 51 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Distinguished Young and Middle-aged Scholar of Shandong University, Innovation and Development Joint Fund of Natural Science Foundation of Shandong Province.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Eltrombopag was approved as a first‐line treatment for patients older than 2 years old with severe aplastic anemia (SAA). However, data on eltrombopag in children with different types of aplastic anemia (AA), especially non‐severe AA (NSAA), are limited. We performed a prospective, single‐arm, and observational study to investigate eltrombopag's efficacy, safety, and pharmacokinetics in children with NSAA, SAA, and very severe AA (VSAA). The efficacy and safety were assessed every 3 months. The population pharmacokinetic (PPK) model was used to depict the pharmacokinetic profile of eltrombopag. Twenty‐three AA children with an average age of 7.9 (range of 3.0‐14.0) years were enrolled. The response (complete and partial response) rate was 12.5%, 50.0%, and 100.0% after 3, 6, and 12 months in patients with NSAA. For patients with SAA and VSAA, these response rates were 46.7%, 61.5%, and 87.5%. Hepatotoxicity occurred in one patient. Fifty‐three blood samples were used to build the PPK model. Body weight was the only covariate for apparent clearance (CL/F) and volume of distribution. The allele‐T carrier of adenosine triphosphate‐binding cassette transporter G2 was found to increase eltrombopag's clearance. However, when normalized by weight, the clearance between the wild‐type and variant showed no statistical difference. In patients with response, children with NSAA exhibited lower area under the curve from time zero to infinity, higher CL/F, and higher weight‐adjusted CL/F than those with SAA or VSAA. However, the differences were not statistically significant. The results may support further individualized treatment of eltrombopag in children with AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacy, Key Laboratory of Chemical Biology (Ministry of Education), School of Pharmaceutical Sciences, Cheeloo College of Medicine, Shandong University, Jinan, China.
- State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sc…
- Tianjin Institutes of Health Science, Tianjin, China.
- Department of Pharmacy, The Second Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.
- Department of Pharmacy, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
- Division of Clinical Pharmacology, Children's National Hospital, Washington, DC, USA.
ORCID-Profile: Wei Zhao
Förderung
- National Natural Science Foundation of China
- Distinguished Young and Middle-aged Scholar of Shandong University
- Innovation and Development Joint Fund of Natural Science Foundation of Shandong Province
- Natural Science Foundation of Shandong Province
- Postdoctoral Innovation Project of Shandong Province
- CAMS Innovation Fund for Medical Sciences
- Taishan Scholar Program of Shandong Province
Zitieren
APA
Zhang, W., Chang, L. X., Zhao, B. B., Zheng, Y., Shan, D. D., Tang, B. H., Yang, F., Zhou, Y., Hao, G. X., Zhang, Y. H., van den Anker, J., Zhu, X. F., Zhang, L., & Zhao, W. (2024). Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia. The Journal of Clinical Pharmacology. https://doi.org/10.1002/jcph.2430
Vancouver
Zhang W, Chang LX, Zhao BB, Zheng Y, Shan DD, Tang BH, et al. Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia. The Journal of Clinical Pharmacology. 2024. doi:10.1002/jcph.2430
BibTeX
@article{Zhang2024,
author = {Zhang, Wei and Chang, Li-Xian and Zhao, Bei-Bei and Zheng, Yi and Shan, Dan-Dan and Tang, Bo-Hao and Yang, Fan and Zhou, Yue and Hao, Guo-Xiang and Zhang, Ya-Hui and van den Anker, John and Zhu, Xiao-Fan and Zhang, Li and Zhao, Wei},
title = {Efficacy, Safety, and Population Pharmacokinetics of Eltrombopag in Children with Different Severities of Aplastic Anemia},
journal = {The Journal of Clinical Pharmacology},
year = {2024},
doi = {10.1002/jcph.2430}
}
EUVIMED